We are live on ! Find out more

Pluri

PLUR

Market cap $14.1M

1.14 USD

-0.03

2.56%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

1.12

-0.02

1.75%

1 day

-2.56%

5 days

-14.93%

1 month

-28.75%

3 months

-49.33%

6 months

-65.35%

Year to date

-61.87%

1 year

-76.69%

5 years

-95.19%

10 years

-99.12%

About: Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Employees: 113

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 Common Shares (or Common Share equivalents in lieu thereof) at a purchase price of $1.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $3.3 million, before deducting placement agent commissions and other offering expenses.

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has successfully completed the cosmetic regulatory registration and notification process in the UK, supporting a coming commercial launch of its regenerative aesthetics product, Regenativo+, marking another significant milestone in the Company's commercialization strategy.

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Plurilock Announces Results of Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecurity company, is pleased to announce the results of its Annual General Meeting (the "Meeting") of shareholders held on June 16, 2026. All resolutions presented to the shareholders were approved.

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has completed the development and U.S. cosmetic product listings of two flagship regenerative aesthetic products - Regenativo+ and Placento+, clearing the path for commercial launch in the United States.

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey.

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Strategic initiative to address Ukraine's urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it has signed an exclusive collaboration agreement with Hemafund Ltd. (“Hemafund”), a Ukrainian umbilical cord blood bank with clinical and research laboratories and facilities specializing in cell preservation and cryostorage (the “Collaboration” or the “Collaboration Agreement”).

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

See News Rankings

Price charts implemented using Lightweight Charts™